gs-9620 and loxoribine

gs-9620 has been researched along with loxoribine* in 1 studies

Other Studies

1 other study(ies) available for gs-9620 and loxoribine

ArticleYear
TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:5

    Norovirus infections are a significant health and economic burden globally, accounting for hundreds of millions of cases of acute gastroenteritis every year. In the absence of an approved norovirus vaccine, there is an urgent need to develop antivirals to treat chronic infections and provide prophylactic therapy to limit viral spread during epidemics and pandemics. Toll-like receptor (TLR) agonists have been explored widely for their antiviral potential, and several are progressing through clinical trials for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) and as adjuvants for norovirus viruslike particle (VLP) vaccines. However, norovirus therapies in development are largely direct-acting antivirals (DAAs) with fewer compounds that target the host. Our aim was to assess the antiviral potential of TLR7 agonist immunomodulators on norovirus infection using the murine norovirus (MNV) and human Norwalk replicon models. TLR7 agonists R-848, Gardiquimod, GS-9620, R-837, and loxoribine were screened using a plaque reduction assay, and each displayed inhibition of MNV replication (50% effective concentrations [EC

    Topics: Aminoquinolines; Animals; Antiviral Agents; Caliciviridae Infections; Cell Line; Guanosine; Humans; Imidazoles; Imiquimod; Mice; Pteridines; RAW 264.7 Cells; Toll-Like Receptor 7; Virus Replication

2018